19.04.2021 Carl Zeiss Meditec AG  DE0005313704

DGAP-Adhoc: Carl Zeiss Meditec AG returns to significant revenue growth in second quarter 2020/21


 

DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Half Year Results
Carl Zeiss Meditec AG returns to significant revenue growth in second quarter 2020/21

19-Apr-2021 / 10:06 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec AG returns to significant revenue growth in second quarter 2020/21

Jena, April 19, 2021

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 767.4 million in the first half of fiscal year 2020/21 (previous year: EUR 714.9 million). This corresponds to a revenue development of +7.3% vs. the past year (after adjustment for currency effects[1]: +10.5%). In the second quarter of FY 2020/21, revenue amounted to EUR 398.5 million (past year: EUR 345.3 million) - a growth rate of +15.4% (after adjustment for currency effects: +18.8%).

Earnings before interest and taxes (EBIT)[2] amounted to EUR 162.7 million in the first half of FY 2020/21 (past year: EUR 102.5 million). EBIT margin (EBIT / revenue) was 21.2% (past year 14.3%). In the second quarter of FY 2020/21, EBIT amounted to EUR 89.3 million (past year: EUR 45.7 million). EBIT margin was 22.4% (past year: 13.2%). EBIT benefitted in part from a favorable development of product mix as well as a continuing low level of sales and marketing expenses due to the COVID-19 pandemic, compared to the past year.

Earnings per share (EPS)[3] amounted to EUR 1.12 (past year: EUR 0.71) for the first half of FY 2020/21. In the second quarter, EPS amounted to EUR 0.60 (past year: EUR 0.28).

Full results for the first half 2020/21 will be published on May 10, 2021.

During the further course of FY 2020/21, the company expects an ongoing normalization of business development. This expectation is based on the assumption that there will be no renewed deterioration in the global pandemic situation.

Revenue is expected to reach around EUR 1.6 billion (past year: EUR 1,335.5 million) in FY 2020/21. EBIT margin for FY 2020/21 is projected to reach a level of approximately 20% (past year: 13.3%), with significant support from lower than usual sales and marketing expenses in the current year. The company's mid-term margin outlook remains unchanged: to generate an EBIT margin sustainably above the level of 18%.
 
 

 

Contact for investors and press
Sebastian Frericks
Head of Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: [email protected]

 

[1] Currency-adjusted revenue growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.
[2] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).
[3] Earnings per share (also EPS) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated according to IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).


19-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: [email protected]
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1186148

 
End of Announcement DGAP News Service

1186148  19-Apr-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1186148&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1.189,90 1.280,86 1.459,32 1.335,45 1.646,79 1.902,84 2.089,30
EBITDA1,2 205,07 228,41 313,03 237,98 435,20 466,65 422,19
EBITDA-Marge3 17,23 17,83 21,45 17,82 26,43 24,52
EBIT1,4 180,83 197,13 264,66 177,55 373,61 396,88 348,12
EBIT-Marge5 15,20 15,39 18,14 13,30 22,69 20,86 16,66
Jahresüberschuss1 135,78 126,23 160,58 123,42 237,52 295,91 292,01
Netto-Marge6 11,41 9,86 11,00 9,24 14,42 15,55 13,98
Cashflow1,7 37,73 187,21 219,63 178,53 362,66 188,20 250,86
Ergebnis je Aktie8 1,57 1,41 1,79 1,37 2,64 3,29 3,25
Dividende8 0,55 0,55 0,65 0,50 0,90 1,10 0,42
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Carl Zeiss Meditec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
531370 119,400 Halten 10.679,20
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
33,63 36,03 0,93 58,53
KBV KCV KUV EV/EBITDA
5,18 42,57 5,11 23,23
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,10 1,10 0,92 21.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
09.02.2024 08.05.2024 06.08.2024 12.12.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
9,57% 24,61% 20,80% -6,02%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Carl Zeiss Meditec AG  ISIN: DE0005313704 können Sie bei EQS abrufen


Medtech , 531370 , AFX , XETR:AFX